ReviewFrontiers in aging neuroscience2018
Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer's Disease Prevention.
Review in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Deep Learning in Alzheimer's Disease: Diagnostic Classification and Prognostic Prediction Using Neuroimaging Data.Frontiers in aging neuroscience · 2019Pooled it
- A proficient approach for the classification of Alzheimer's disease using a hybridization of machine learning and deep learning.Scientific reports · 2024Article
- Impact of mechanical ventilation on clinical outcomes in ICU-admitted Alzheimer's disease patients: a retrospective cohort study.Frontiers in public health · 2024Article
- Baseline Profiles of Drug Prescriptions Prior to Diagnosis of Mild Cognitive Impairment (MCI) Obtained by Latent Class Analysis (LCA), and Assessment of Their Association with Conversion to Dementia.Healthcare (Basel, Switzerland) · 2023Article
- Diet and lifestyle impact the development and progression of Alzheimer's dementia.Frontiers in nutrition · 2023Review
- Effect of Alzheimer Disease on Prognosis of Intensive Care Unit (ICU) Patients: A Propensity Score Matching Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- A Comprehensive Survey on the Detection, Classification, and Challenges of Neurological Disorders.Biology · 2022Review
- Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- The Role of Nutrition in Individualized Alzheimer's Risk Reduction.Current nutrition reports · 2020Review
- Interactions between Curcumin Derivatives and Amyloid-β Fibrils: Insights from Molecular Dynamics Simulations.Journal of chemical information and modeling · 2020Article
- Feasibility of Using a Wearable Biosensor Device in Patients at Risk for Alzheimer's Disease Dementia.The journal of prevention of Alzheimer's disease · 2020Article
- Individualized clinical management of patients at risk for Alzheimer's dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2019Article
- Editorial: Cognitive and Brain Aging: Interventions to Promote Well-Being in Old Age.Frontiers in aging neuroscience · 2019Article
- N-of-1 Clinical Trials in Nutritional Interventions Directed at Improving Cognitive Function.Frontiers in nutrition · 2019Review
- The clinical practice of risk reduction for Alzheimer's disease: A precision medicine approach.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Observational
- Alzheimer's "Prevention" vs. "Risk Reduction": Transcending Semantics for Clinical Practice.Frontiers in neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative dementia that affects nearly 50 million people worldwide and is a major source of morbidity, mortality, and healthcare expenditure. While there have been many attempts to develop disease-modifying therapies for late-onset AD, none have so far shown efficacy in humans. However, the long latency between the initial neuronal changes and onset of symptoms, the ability to identify patients at risk based on family history and genetic markers, and the emergence of AD biomarkers for preclinical disease suggests that early risk-reducing interventions may be able to decrease the incidence of, delay or prevent AD. In this review, we discuss six mechanisms-dysregulation of glucose metabolism, inflammation, oxidative stress, trophic factor release, amyloid burden, and calcium toxicity-involved in AD pathogenesis that offer promising targets for risk-reducing interventions. In addition, we offer a blueprint for a multi-modality AD risk reduction program that can be clinically implemented with the current state of knowledge. Focused risk reduction aimed at particular pathological factors may transform AD to a preventable disorder in select cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.